Pfizer's TUKYSA regimen wins FDA approval as front-line maintenance treatment for HER2+ metastatic breast cancer

Pfizer's TUKYSA regimen received FDA approval as a front-line maintenance treatment for HER2+ metastatic breast cancer, according to a desk report.

Detected & updated continuously · Source: Nebula

Story subjects

Pfizer Inc.Food and Drug Administration

Track sentiment and mindshare across stocks and crypto in Nebula.